JP2020536923A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536923A5 JP2020536923A5 JP2020520587A JP2020520587A JP2020536923A5 JP 2020536923 A5 JP2020536923 A5 JP 2020536923A5 JP 2020520587 A JP2020520587 A JP 2020520587A JP 2020520587 A JP2020520587 A JP 2020520587A JP 2020536923 A5 JP2020536923 A5 JP 2020536923A5
- Authority
- JP
- Japan
- Prior art keywords
- blinatumomab
- pembrolizumab
- variant
- administered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960003008 blinatumomab Drugs 0.000 claims 204
- 229960002621 pembrolizumab Drugs 0.000 claims 172
- 239000000427 antigen Substances 0.000 claims 86
- 102000036639 antigens Human genes 0.000 claims 86
- 108091007433 antigens Proteins 0.000 claims 86
- 239000012634 fragment Substances 0.000 claims 86
- 239000008194 pharmaceutical composition Substances 0.000 claims 44
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 19
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 10
- 238000007596 consolidation process Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023164647A JP2024001071A (ja) | 2017-10-13 | 2023-09-27 | びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762571870P | 2017-10-13 | 2017-10-13 | |
| US62/571,870 | 2017-10-13 | ||
| PCT/US2018/055667 WO2019075366A1 (en) | 2017-10-13 | 2018-10-12 | COMPOSITIONS AND METHODS FOR TREATING DIFFUSED LYMPHOMA WITH LARGE B CELLS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023164647A Division JP2024001071A (ja) | 2017-10-13 | 2023-09-27 | びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536923A JP2020536923A (ja) | 2020-12-17 |
| JP2020536923A5 true JP2020536923A5 (enExample) | 2021-11-18 |
Family
ID=64110107
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520587A Pending JP2020536923A (ja) | 2017-10-13 | 2018-10-12 | びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法 |
| JP2023164647A Pending JP2024001071A (ja) | 2017-10-13 | 2023-09-27 | びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023164647A Pending JP2024001071A (ja) | 2017-10-13 | 2023-09-27 | びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200262919A1 (enExample) |
| EP (1) | EP3694520A1 (enExample) |
| JP (2) | JP2020536923A (enExample) |
| KR (1) | KR20200068655A (enExample) |
| CN (1) | CN111212646A (enExample) |
| AU (1) | AU2018347457A1 (enExample) |
| BR (1) | BR112020007203A2 (enExample) |
| CA (1) | CA3075291A1 (enExample) |
| CL (1) | CL2020000973A1 (enExample) |
| EA (1) | EA202090565A1 (enExample) |
| IL (1) | IL273805A (enExample) |
| MX (2) | MX2020003395A (enExample) |
| SG (1) | SG11202002374RA (enExample) |
| TW (1) | TW201922283A (enExample) |
| WO (1) | WO2019075366A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| TW202200615A (zh) * | 2020-03-12 | 2022-01-01 | 美商安進公司 | 用於治療和預防患者的crs之方法 |
| WO2022081529A1 (en) * | 2020-10-12 | 2022-04-21 | Greffex, Inc. | Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses |
| IL320558A (en) * | 2022-11-01 | 2025-07-01 | Teneotwo Inc | Methods of treating non-hodgkin lymphoma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| RU2005141512A (ru) | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
| PT2520590T (pt) | 2007-04-03 | 2018-11-14 | Amgen Res Munich Gmbh | Domínio de ligação específico de espécies cruzadas |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| KR20180014009A (ko) | 2015-05-29 | 2018-02-07 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합 |
| US10973822B2 (en) * | 2015-07-02 | 2021-04-13 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
-
2018
- 2018-10-12 US US16/648,568 patent/US20200262919A1/en not_active Abandoned
- 2018-10-12 WO PCT/US2018/055667 patent/WO2019075366A1/en not_active Ceased
- 2018-10-12 EP EP18797306.0A patent/EP3694520A1/en not_active Withdrawn
- 2018-10-12 MX MX2020003395A patent/MX2020003395A/es unknown
- 2018-10-12 AU AU2018347457A patent/AU2018347457A1/en not_active Abandoned
- 2018-10-12 CN CN201880066675.2A patent/CN111212646A/zh active Pending
- 2018-10-12 BR BR112020007203-6A patent/BR112020007203A2/pt unknown
- 2018-10-12 CA CA3075291A patent/CA3075291A1/en active Pending
- 2018-10-12 SG SG11202002374RA patent/SG11202002374RA/en unknown
- 2018-10-12 KR KR1020207009219A patent/KR20200068655A/ko not_active Ceased
- 2018-10-12 JP JP2020520587A patent/JP2020536923A/ja active Pending
- 2018-10-12 EA EA202090565A patent/EA202090565A1/ru unknown
- 2018-10-15 TW TW107136236A patent/TW201922283A/zh unknown
-
2020
- 2020-04-05 IL IL273805A patent/IL273805A/en unknown
- 2020-04-09 CL CL2020000973A patent/CL2020000973A1/es unknown
- 2020-07-13 MX MX2024001888A patent/MX2024001888A/es unknown
-
2023
- 2023-09-27 JP JP2023164647A patent/JP2024001071A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536923A5 (enExample) | ||
| JP2015187157A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2017226708A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2018193377A5 (enExample) | ||
| JP2017149726A5 (enExample) | ||
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| JP2017048208A5 (enExample) | ||
| JP2009545600A5 (enExample) | ||
| JP2018506550A5 (enExample) | ||
| JP2013155188A5 (enExample) | ||
| JP2018505882A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| JP2016515586A5 (enExample) | ||
| JP2006513184A5 (enExample) | ||
| IL307992A (en) | Parasitic formulations containing isoxazoline and methods for treating blepharitis | |
| JP2017512194A5 (enExample) | ||
| JP2012502103A5 (enExample) | ||
| JP2015507020A5 (enExample) | ||
| JP2018506533A5 (enExample) | ||
| JP2017527551A5 (enExample) | ||
| JP2006514681A5 (enExample) | ||
| JP2010504307A5 (enExample) | ||
| JP2021517886A5 (enExample) |